Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk

References

• GBD 2017. Causes of death collaborators. global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 19802017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736–1788.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and Cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–415.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, Pencina KM, Lloyd-Jones D, et al. The expected 30-year benefits of early versus delayed primary prevention of Cardiovascular Disease by lipid lowering. Circulation. 2020;142(9):827–837.
   PubMed Web of Science ®Google Scholar
• Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824–835.
   PubMed Web of Science ®Google Scholar
• Escobar C, Anguita M, Arrarte V, et al., Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed). 2020;73(2):161–167.
   PubMed Web of Science ®Google Scholar
• Strilchuk L, Tocci G, Fogacci F, et al. An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opin Pharmacother. 2020;21(5):531–539.
   PubMed Web of Science ®Google Scholar
• Lamb YN. Rosuvastatin/Ezetimibe: a review in Hypercholesterolemia. Am J Cardiovasc Drugs. 2020;20(4):381–392.
   PubMed Web of Science ®Google Scholar
• Rosuvastatin and ezetimibe. Summary of product characteristics. [cied 2020 Dec 18]. Available from: https://mri.cts-mrp.eu/human/downloads/NL_H_3647_001_FinalSPC.pdf
   Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152–160.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER. Am J Cardiol. 2010;105(1):69–76.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xing L, Jia X, et al. Comparative lipid-lowering/increasing efficacy of 7 statins in patients with Dyslipidemia, Cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials. Cardiovasc Ther. 2020;3987065:2020.
   Google Scholar
• Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins – clinical evidence. Curr Pharm Des. 2009;15(5):479–489.
   PubMed Web of Science ®Google Scholar
• Fan CH, Hao Y, Liu YH, et al. Anti-inflammatory effects of rosuvastatin treatment on coronary artery ectasia patients of different age groups. BMC Cardiovasc Disord. 2020;20(1):330.
   PubMed Web of Science ®Google Scholar
• Slhessarenko JR, Hirata M, Sousa A, et al. Effect of preloading with high dose of rosuvastatin on serum levels of inflammatory markers after percutaneous coronary intervention. J Invasive Cardiol. 2020;32(9):335–341.
   PubMed Web of Science ®Google Scholar
• Kini AS, Baber U, Kovacic J, et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW Trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62(1):21–29.
   PubMed Web of Science ®Google Scholar
• Naresh S, Bitla AR, Rao PVLNS, et al. Efficacy of oral rosuvastatin intervention on HDL and its associated proteins in men with type 2 diabetes mellitus. Endocrine. 2021;71(1):76–86.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Fonseca FA, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes. 2009;2(6):616–623.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Rosuvastatin and diabetes: when the evidences talk. Cardiovasc Hematol Agents Med Chem. 2013;11(2):115–124.
   PubMedGoogle Scholar
• Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–571.
   PubMed Web of Science ®Google Scholar
• Hsia J, MacFadyen JG, Monyak J, et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. the jupiter trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol. 2011;57(16):1666–1675.
   PubMed Web of Science ®Google Scholar
• Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121(9):1069–1077.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55(12):1266–1273.
   PubMed Web of Science ®Google Scholar
• Everett BM, Glynn RJ, MacFadyen JG, et al. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER. Circulation. 2010;121(1):143–150.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Macfadyen JG, Nordestgaard BG, et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for “intermediate risk”. Circ Cardiovasc Qual Outcomes. 2010;3(5):447–452.
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152(8):488–496.
   PubMed Web of Science ®Google Scholar
• Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk = 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J. 2011;32(1):75–83.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Bosch J, Dagenais G, et al. HOPE-3 Investigators. cholesterol lowering in intermediate-risk persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2021–2031.
   PubMed Web of Science ®Google Scholar
• Wander GS, Hukkeri MYK, Yalagudri S, et al. Rosuvastatin: role in Secondary Prevention of Cardiovascular Disease. J Assoc Physicians India. 2018;66(3):70–74.
   PubMedGoogle Scholar
• Clearfield MB, Amerena J, Bassand JP, et al., Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia–Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials. 7(1): 35. 2006.
   PubMedGoogle Scholar
• Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–1565.
   PubMed Web of Science ®Google Scholar
• Crouse JR 3rd, Js R, Wa R, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344–1353.
   PubMed Web of Science ®Google Scholar
• Underhill HR, Yuan C, Zhao XQ, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J. 2008;155(3):584.
   PubMed Web of Science ®Google Scholar
• Takayama T, Hiro T, Yamagishi M, et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009;73(11):2110–2117.
   PubMed Web of Science ®Google Scholar
• Hall AS, Jackson BM, Farrin AJ, et al. A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the secondary prevention of acute coronary events–reduction of cholesterol to key European targets trial. Eur J Cardiovasc Prev Rehabil. 2009;16(6):712–721.
   PubMedGoogle Scholar
• Lablanche JM, Leone A, Merkely B, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study. Arch Cardiovasc Dis. 2010;103(3):160–169.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–2087.
   PubMed Web of Science ®Google Scholar
• Pitt B, Loscalzo J, Monyak J, et al., Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol. 2012;109(9):1239–1246.
   PubMed Web of Science ®Google Scholar
• Zhang J, Feng R, Ferdous M, et al. Effect of 2 different dosages of rosuvastatin on prognosis of acute myocardial infarction patients with new-onset atrial fibrillation in Jinan, China. Med Sci Monit. 2020;26:e925666.
   PubMed Web of Science ®Google Scholar
• Luo R, Sun X, Shen F, et al. Effects of high-dose rosuvastatin on ventricular remodelling and cardiac function in st-segment elevation Myocardial infarction. Drug Des Devel Ther. 2020;14:3891–3898.
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Borderi M, et al. Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome. Infect Dis (Lond). 2021;53(2):81–88.
   PubMed Web of Science ®Google Scholar
• Liu D, Shen T, Ren C, et al. The effects of atorvastatin and rosuvastatin on exercise tolerance in patients with coronary heart disease. Expert Opin Drug Saf. 2020;19(9):1203–1208.
   PubMed Web of Science ®Google Scholar
• He W, Cao M, Li Z. Effects of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST-elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Drug Dev Res. 2020;81(5):551–556.
   PubMed Web of Science ®Google Scholar
• Perez-Calahorra S, Laclaustra M, Marco-Benedi V, et al. Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. Lipids Health Dis. 2019;18(1):216.
   PubMed Web of Science ®Google Scholar
• Kwak A, Kim JH, Choi CU, et al. Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over. Int J Clin Pharm. 2019;41(2):460–469.
   PubMed Web of Science ®Google Scholar
• Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe lipid-lowering trial on prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): a randomized, controlled trial. Circulation. 2019;140(12):992–1003.
   PubMed Web of Science ®Google Scholar
• Hammersley D, Signy M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Ther Adv Chronic Dis. 2017;8(1):4–11.
   PubMed Web of Science ®Google Scholar
• Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251–261.
   PubMed Web of Science ®Google Scholar
• Ta P, Cm B, Veltri E, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009;103(3):369–374.
   PubMed Web of Science ®Google Scholar
• Tsunoda T, Nozue T, Yamada M, et al. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract. 2013;100(1):46–52.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192.
   PubMed Web of Science ®Google Scholar
• Cp C, Ma B, Rp G, et al., Ezetimibe added to statin therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Bach RG, Cannon CP, Giugliano RP, et al. Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after Acute Coronary Syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2019;4(9):846–854.
   PubMed Web of Science ®Google Scholar
• Verschuren L, Radonjic M, Wielinga PY, et al. Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy. Pharmacogenet Genomics. 2012;22(12):837–845.
   PubMed Web of Science ®Google Scholar
• Kim CH, An H, Kim SH, et al. Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. Drug Des Devel Ther. 2017;11:3461–3469.
   PubMed Web of Science ®Google Scholar
• Kim H, Choi HY, Kim YH, et al. Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers. Drug Des Devel Ther. 2018;12:815–821.
   PubMed Web of Science ®Google Scholar
• Hwang I, Park SI, Lee SH, et al. Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects. Transl Clin Pharmacol. 2018;26(1):16–24.
   PubMedGoogle Scholar
• Kang WY, Seong SJ, Ohk B, et al. Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects. Int J Clin Pharmacol Ther. 2018;56(1):43–52.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004;20(8):1185–1195.
   PubMed Web of Science ®Google Scholar
• Rhee MY, Kim KJ, Kim SH, et al. Ezetimibe and rosuvastatin combination treatment can reduce the dose of rosuvastatin without compromising its lipid-lowering efficacy. Clin Ther. 2019;41(12):2571–2592.
   PubMed Web of Science ®Google Scholar
• Hong SJ, Jeong HS, Ahn JC, et al., A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: i-ROSETTE (Ildong rosuvastatin & ezetimibe for hypercholesterolemia) randomized controlled trial. Clin Ther. 2018;40(2):226–241.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Kim SH, Yoon YW, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROSE (Multicenter randomized study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016;34(5):371–382.
   PubMed Web of Science ®Google Scholar
• Kim W, Yoon YE, Shin S-H, et al., Efficacy and safety of ezetimibe and rosuvastatin combination therapy versus those of rosuvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2018;40(6):993–1013.
   PubMed Web of Science ®Google Scholar
• Vattimo ACA, Fonseca FAH, Morais DC, et al. Efficacy and tolerability of a fixed-dose combination of rosuvastatin and ezetimibe compared with a fixed-dose combination of simvastatin and ezetimibe in Brazilian patients with primary hypercholesterolemia or mixed dyslipidemia: a multicenter, randomized trial. Curr Ther Res Clin Exp. 2020;93:100595.
   PubMed Web of Science ®Google Scholar
• Yamazaki D, Ishida M, Watanabe H, et al. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis. 2013;12(1):9.
   PubMedGoogle Scholar
• Ren Y, Zhu H, Fan Z, et al. Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Exp Ther Med. 2017;14(5):4942–4950.
   PubMed Web of Science ®Google Scholar
• Lee WD, Kim BK, Park JY, et al. Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. Eur J Gastroenterol Hepatol. 2020;32(12):1538–1544.
   PubMed Web of Science ®Google Scholar
• Lee J, Hwang YC, Lee WJ, et al., Comparison of the efficacy and safety of rosuvastatin/ezetimibe combination therapy and rosuvastatin monotherapy on lipoprotein in patients with type 2 diabetes: multicenter randomized controlled study. Diabetes Ther. 2020;11(4):859–871.
   PubMed Web of Science ®Google Scholar
• Torimoto K, Okada Y, Mori H, et al. Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 2013;12(1):137.
   PubMedGoogle Scholar
• Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE study). Am J Cardiol. 2011;108(4):523–530.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Weiss R, Moccetti T, et al., Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673–680.
   PubMed Web of Science ®Google Scholar
• Yang Y-J, Lee S-H, Kim BS, et al. Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk. Clin Ther. 2017;39(1):107–117.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Raya JL, et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study. Atherosclerosis. 2014;232(1):86–93.
   PubMed Web of Science ®Google Scholar
• Ran D, Nie HJ, Gao YL, et al. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol. 2017;235:49–55.
   PubMed Web of Science ®Google Scholar
• Obonska K, Kasprzak M, Tymosiak K, et al., Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): a randomized, crossover study - preliminary results. Cardiol J. 2021;28(1):58–66.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao X, Li L, et al. Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart Lung Circ. 2016;25(5):459–465.
   PubMed Web of Science ®Google Scholar
• Masuda J, Tanigawa T, Yamada T, et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J. 2015;56(3):278–285.
   PubMed Web of Science ®Google Scholar
• Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. J Cardiovasc Pharmacol Ther. 2013;18(1):5–12.
   PubMed Web of Science ®Google Scholar
• Drexel H, Coats AJS, Spoletini I, et al., An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: barriers to be overcome. Eur Heart J Cardiovasc Pharmacother. 2020;6(2):115–121.
   PubMedGoogle Scholar
• Barrios V, Escobar C. Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert Rev Cardiovasc Ther. 2009;7(11):1317–1327.
   PubMedGoogle Scholar
• Barrios V, Escobar C. Rosuvastatin and cardiovascular continuum when time is important. J Am Coll Cardiol. 2010;55(15): 1645–1646. author reply 1646.
   PubMed Web of Science ®Google Scholar
• Lorenzi M, Ambegaonkar B, Baxter CA, et al. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clin Res Cardiol. 2019;108(5):487–509.
   PubMed Web of Science ®Google Scholar
• Yu M, Liang C, Kong Q, et al. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Lipids Health Dis. 2020;19(1):1.
   PubMed Web of Science ®Google Scholar
• Katzmann JL, Sorio-Vilela F, Dornstauder E, et al. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. Clin Res Cardiol. Online ahead of print Sep 19 2020. 10.1007/s00392-020-01740-8
   PubMed Web of Science ®Google Scholar
• Barkas F, Elisaf M, Liberopoulos E, et al. Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidol. 2016;10(2):306–313.
   PubMed Web of Science ®Google Scholar
• Salam A, Huffman MD, Kanukula R, et al. Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: an overview of efficacy, safety, and cost. J Clin Hypertens (Greenwich). 2020;22(10):1769–1779.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Kim JS, Labreuche J, et al. Treat stroke to target investigators. a comparison of two ldl cholesterol targets after ischemic stroke. N Engl J Med. 2020;382(1):9.
   PubMed Web of Science ®Google Scholar
• Davies GM, Vyas A, Baxter CA. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States. J Med Econ. 2017;20(7):723–731.
   PubMed Web of Science ®Google Scholar
• Yang H, Li N, Zhou Y, et al. Cost-effectiveness analysis of ezetimibe as the add-on treatment to moderate-dose rosuvastatin versus high-dose rosuvastatin in the secondary prevention of cardiovascular diseases in china: a Markov model analysis. Drug Des Devel Ther. 2020;14:157–165.
   PubMed Web of Science ®Google Scholar